{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:01:22Z","timestamp":1777723282997,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T00:00:00Z","timestamp":1441411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Asociacion de Reumatologos del Hospital de Cruces","award":["05\/2015"],"award-info":[{"award-number":["05\/2015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00296-015-3355-5","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T05:59:13Z","timestamp":1441432753000},"page":"1857-1861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase"],"prefix":"10.1007","volume":"35","author":[{"given":"Fernando","family":"Perez-Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra Pamela","family":"Chinchilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Atxotegi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irati","family":"Urionag\u00fcena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Herrero-Beites","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angeles","family":"Aniel-Quiroga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,5]]},"reference":[{"key":"3355_CR1","unstructured":"European Medicines Agency (2008) EPACHMP assessment report for Adenuric. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000777\/WC500021812.pdf"},{"issue":"8","key":"3355_CR2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","volume":"46","author":"RO Day","year":"2007","unstructured":"Day RO, Graham GG, Hicks M, McLachlan A, Stocker SL, Williams KM (2007) Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 46(8):623\u2013644","journal-title":"Clin Pharmacokinet"},{"key":"3355_CR3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.rhu.0000164822.98163.22","volume":"11","author":"F Perez-Ruiz","year":"2005","unstructured":"Perez-Ruiz F, Hernando I, Villar I, Nolla JM (2005) Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels. Another insight to allopurinol-related toxicity. J Clin Rheumatol 11:129\u2013133","journal-title":"J Clin Rheumatol"},{"issue":"8\u20139","key":"3355_CR4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1081\/NCN-200027377","volume":"23","author":"S Hoshide","year":"2004","unstructured":"Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K et al (2004) PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 23(8\u20139):1117\u20131118","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1","key":"3355_CR5","first-page":"e16","volume":"18","author":"J Wang","year":"2013","unstructured":"Wang J, Ma X, Qu S, Li Y, Han L, Sun X et al (2013) High prevalence of subclinical thyroid dysfunction and the relationship between thyrotropin levels and cardiovascular risk factors in residents of the coastal area of China. Exp Clin Cardiol 18(1):e16\u2013e20","journal-title":"Exp Clin Cardiol"},{"issue":"8","key":"3355_CR6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/BF03345734","volume":"32","author":"O Makay","year":"2009","unstructured":"Makay O, Yenisey C, Icoz G, Genc SN, Ozgen G, Akyildiz M et al (2009) The role of allopurinol on oxidative stress in experimental hyperthyroidism. J Endocrinol Investig 32(8):641\u2013646","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"3355_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0002-9343(94)90005-1","volume":"97","author":"AR Erickson","year":"1994","unstructured":"Erickson AR, Enzenauer RJ, Nordstrom DM, Merenich JA (1994) The prevalence of hypothyroidism in gout. Am J Med 97(3):231\u2013234","journal-title":"Am J Med"},{"key":"3355_CR8","doi-asserted-by":"crossref","first-page":"e114579","DOI":"10.1371\/journal.pone.0114579","volume":"9","author":"LC See","year":"2014","unstructured":"See LC, Kuo CF, Yu KH, Luo SF, Chou SF et al (2014) Hyperthyroid and hypothyroid status was strongly associated with gout and weakly associated with hyperuricaemia. PLoS one 9:e114579","journal-title":"PLoS one"},{"issue":"5","key":"3355_CR9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/17460816.3.5.421","volume":"3","author":"F Perez-Ruiz","year":"2008","unstructured":"Perez-Ruiz F, Dalbeth N, Schlesinger N (2008) Febuxostat, a novel drug for the treatment of hyperuricemia of gout. Future Rheumatol 3(5):421\u2013427","journal-title":"Future Rheumatol"},{"issue":"6","key":"3355_CR10","first-page":"661","volume":"19","author":"N Giordano","year":"2001","unstructured":"Giordano N, Santacroce C, Mattii G, Geraci S, Amendola A, Gennari C (2001) Hyperuricemia and gout in thyroid endocrine disorders. Clin Exp Rheumatol 19(6):661\u2013665","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"3355_CR11","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","volume":"63","author":"F Perez-Ruiz","year":"2011","unstructured":"Perez-Ruiz F, Herrero-Beites AM, Carmona L (2011) A two-stage approach to the treatment of hyperuricemia in gout: the \u201cdirty dish\u201d hypothesis. Arthr Rheum 63(12):4002\u20134006","journal-title":"Arthr Rheum"},{"issue":"8","key":"3355_CR12","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthr Rheum 64(8):2529\u20132536","journal-title":"Arthr Rheum"},{"issue":"1\u20132","key":"3355_CR13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.vetpar.2013.04.038","volume":"197","author":"MN Saridimichelakis","year":"2013","unstructured":"Saridimichelakis MN, Xenoulis PG, Chatzis MK, Kesabalis D, Steiner JM, Suchodolski JS et al (2013) Thyroid function in 36 dogs with leishmaniosis due to Leishmania infantum before and during treatment with allopurinol with or without meglumine antimonate. Vet Parasitol 197(1\u20132):22\u201328","journal-title":"Vet Parasitol"},{"issue":"8\u20139","key":"3355_CR14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1081\/NCN-200027381","volume":"23","author":"K Komoriya","year":"2004","unstructured":"Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M et al (2004) Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase\/xanthine dehydrogenase (NPSIXO) in patients with gout and\/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 23(8\u20139):1119\u20131122","journal-title":"Nucleosides Nucleotides Nucleic Acids"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3355-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-015-3355-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3355-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:28:33Z","timestamp":1559042913000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-015-3355-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,5]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["3355"],"URL":"https:\/\/doi.org\/10.1007\/s00296-015-3355-5","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,5]]}}}